Alnylam Pharmaceuticals, Inc.

ALNY12 Dec 2024
Healthcare
$254.93
0.00 (-0.14%)
Lowest Today
$251.5
Highest Today
$254.93
Today’s Open
$254.93
Prev. Close
$253.91
52 Week High
$304.39
52 Week Low
$141.98
To Invest in Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Healthcare
ALNY12 Dec 2024
0.00 (-0.14%)
1M
3M
6M
1Y
5Y
Low
$251.5
Day’s Range
High
$254.92
251.5
52 Week Low
$141.98
52-Week Range
52 Week High
$304.39
141.98
1 Day
-
1 Week
-0.4%
1 month return
-9.25%
3 month return
-3.15%
6 month return
+62.31%
1 Year return
+48.42%
3 Years return
+35.93%
5 Years return
+113.61%
10 Years return
-
Institutional Holdings
Capital World Investors
12.8
FMR Inc
11.38
Vanguard Group Inc
9.8
American Funds Growth Fund of Amer A
8.41
Capital Group Growth Fnd of Amer Comp
8.41
BlackRock Inc
7.4
Capital Research Global Investors
4.07

Market Status

Fundamentals
Market Cap
33004.95 mln
PB Ratio
1021.59
PE Ratio
0
Enterprise Value
31574.24 mln
Total Assets
3829.88 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Organisation
Alnylam Pharmaceuticals, Inc.
Employees
2100
Industry
Biotechnology
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step